Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
NCT06727227 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 135
Last updated 2025-07-01
Summary
A longitudinal, non-interventional study with trastuzumab deruxtecan for patients with HER2-low expressing unresectable or metastatic breast cancer in Bulgaria and Slovenia
Conditions
Interventions
- DRUG
-
T-DXd
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-29
- Primary Completion
- 2027-10-31
- Completion
- 2027-10-31
- FDA Drug
- Yes
Countries
- Bulgaria
- Slovenia
Study Locations
More Related Trials
-
Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients
NCT00429247 ·Status: COMPLETED ·Phase: PHASE2
-
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
NCT05744375 ·Status: TERMINATED ·Phase: PHASE2
-
Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years
NCT01433926 ·Status: COMPLETED
-
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
NCT06429761 ·Status: RECRUITING ·Phase: PHASE4
-
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
NCT06750484 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
NCT00667251 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
NCT02748213 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors
NCT02307227 ·Status: COMPLETED ·Phase: PHASE2
-
Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan
NCT06833268 ·Status: COMPLETED
-
A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
NCT01301729 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
NCT01548677 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer
NCT02424682 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer
NCT02144012 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX
NCT06723990 ·Status: RECRUITING
-
Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)
NCT00724360 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
NCT01940497 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
NCT04538742 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
NCT00629278 ·Status: UNKNOWN ·Phase: PHASE3
-
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
NCT06231693 ·Status: TERMINATED
-
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis
NCT02560311 ·Status: UNKNOWN
-
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT04553770 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
NCT02132949 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
NCT02238509 ·Status: UNKNOWN ·Phase: PHASE2